GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2009

Fovea Gains EU Marketing Rights for Dyax’ Candidate in Ophthalmic Uses

  • Fovea obtained a license to develop and commercialize Dyax’ compound DX-88 in retinal diseases. The agreement gives Fovea marketing rights in the EU, while Dyax retains marketing rights for all other territories. If commercialized, each company will pay the other a tiered royalty on net sales in their respective territories.

    Fovea will fund development of DX-88 for the treatment of RVO-induced macular edema (retinal vein occlusion) for approval in worldwide markets. For all other ophthalmic uses of DX-88, Fovea will be responsible for development to meet EU regulatory requirements and Dyax will take care of any additional requirements needed to obtain approval outside the EU.

    “As a potent plasma kallikrein inhibitor, DX-88 has the potential to be a breakthrough therapy in reducing macular edema, a leading cause of visual loss in multiple ophthalmic diseases,” explains Bernard Gilly, president and CEO of Fovea.

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?